ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The development of small molecule tyrosine kinase inhibitors (TKIs), such as Imatinib Mesylate, which inhibits the increased BCR-ABL tyrosine kinase activity, have dramatically improved the prognosis of patients with CML [5, 6].